IQVIA (IQV) Stock Forecast & Price Target

$181.23 -3.62 (-1.96%)

As of 11:36 AM Eastern

IQVIA - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
3

Buy
17

Based on 20 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 3 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$251.22
38.62% Upside

According to the 20 analysts' twelve-month price targets for IQVIA, the average price target is $251.22. The highest price target for IQV is $276.00, while the lowest price target for IQV is $210.00. The average price target represents a forecasted upside of 38.62% from the current price of $181.23.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

IQV Analyst Ratings Over Time

Type	Current Forecast 3/4/24 to 3/4/25	1 Month Ago 2/3/24 to 2/2/25	3 Months Ago 12/5/23 to 12/4/24	1 Year Ago 3/5/23 to 3/4/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	17 Buy rating(s)	14 Buy rating(s)	12 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$251.22	$255.71	$256.50	$256.80
Forecasted Upside	38.62% Upside	27.00% Upside	26.25% Upside	2.08% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	36.04% Upside	30,045.67% Upside	16.01% Upside
News Sentiment Rating	Positive News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/18/2025	JPMorgan Chase & Co. 3 of 5 stars	Anne Samuel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$240.00 ➝ $232.00	+18.50%
2/11/2025	Morgan Stanley 3 of 5 stars	Tejas Savant Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$245.00 ➝ $250.00	+24.05%
2/10/2025	Royal Bank of Canada 4 of 5 stars	S. Dodge Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$270.00 ➝ $270.00	+31.00%
2/10/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$261.00 ➝ $263.00	+26.36%
2/7/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$260.00 ➝ $255.00	+22.06%
2/7/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shlomo Rosenbaum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$273.00 ➝ $261.00	+24.95%
2/3/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$255.00 ➝ $235.00	+17.32%
2/3/2025	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Larsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/21/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$212.00 ➝ $210.00	+6.46%
12/20/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$255.00 ➝ $235.00	+17.54%
12/11/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$260.00 ➝ $248.00	+28.58%
11/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $265.00	+27.09%
11/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $255.00	+22.30%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$280.00 ➝ $250.00	+20.00%
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$276.00	+20.32%
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $265.00	+17.33%
7/31/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$266.00 ➝ $242.00	+1.34%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
12/11/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$190.00 ➝ $225.00	+4.52%
10/10/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$250.00 ➝ $229.00	+14.76%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$260.00	+17.71%
5/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$235.00 ➝ $220.00	+16.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:36 AM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, February 27, 2025. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

IQVIA Holdings Inc. has a strong market presence in the life sciences industry, providing advanced analytics and technology solutions, which positions it well for growth as demand for these services increases.
The company has received multiple "buy" ratings from analysts, indicating strong confidence in its future performance. The average target price is currently $251.22, suggesting potential upside from the current stock price of $190.77.
Recent earnings reports show a return on equity of 28.81%, indicating effective management and profitability, which can attract more investors looking for solid returns.
IQVIA Holdings Inc. has a diverse service offering across various regions, including the Americas, Europe, Africa, and the Asia-Pacific, which helps mitigate risks associated with market fluctuations in any single region.
The company has a relatively low debt-to-equity ratio of 2.12, suggesting that it is not overly reliant on debt for financing, which can be a positive indicator of financial health.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

Despite its strong market position, IQVIA Holdings Inc. recently reported earnings per share (EPS) of $2.90, which missed analysts' consensus estimates of $3.11, raising concerns about its short-term performance.
The stock has experienced volatility, with a 12-month high of $261.73 and a low of $187.62, indicating potential risks for investors who may be sensitive to price fluctuations.
Analysts have recently adjusted their price targets downward, with Barclays reducing their target from $255.00 to $235.00, which may signal a lack of confidence in the stock's near-term growth prospects.
The company has a current ratio of 0.84, which is below 1, indicating that it may face challenges in meeting its short-term liabilities, a potential red flag for investors.
With 1.60% of the stock owned by corporate insiders, there may be limited insider confidence in the stock's future performance, which could be a concern for potential investors.

IQV Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $251.22, with a high forecast of $276.00 and a low forecast of $210.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 3 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.
: According to analysts, IQVIA's stock has a predicted upside of 38.62% based on their 12-month stock forecasts.
: Over the previous 90 days, IQVIA's stock had 1 downgrade by analysts.
: IQVIA has been rated by research analysts at Bank of America, Barclays, BTIG Research, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stephens, Stifel Nicolaus, Truist Financial, UBS Group, and William Blair in the past 90 days.
: Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.90 while the average consensus rating score for "medical" companies is 2.82. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:IQV) was last updated on 3/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target